Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2018
At a glance
- Drugs ABX 464 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept
- Sponsors Abivax
- 04 Sep 2018 According to an Abivax media release, complete data from this study will be present at the upcoming international scientific conferences. Also, will be submitted for publication in a leading medical scientific journal.
- 04 Sep 2018 Status changed from active, no longer recruiting to completed, according to an Abivax media release.
- 04 Sep 2018 Top-line results presented in an Abivax media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History